Janssen Pharmaceutica NV /
Yumanity Therapeutics, Inc.
Janssen Pharmaceutica NV purchases Yumanity product rights
- Terms
- Not stated
- Stage
- Closed
What happened
Janssen Pharmaceutica NV completed its purchase of rights to Yumanity Therapeutics, Inc.’s clinical-stage product candidate YTX-7739, along with its unpartnered pre-clinical and discovery-stage candidates and related intellectual property rights.
The purchase price was $26,000,000 in cash.
The source
Everything on this page comes from the source below.
Janssen Pharmaceutica NV purchases Yumanity product rights
This document is the source for the companies, stage and people on this page.
Original filingUnlock with ProTimeline
Every date the source states, in order. Anything marked ahead is a target the source gives, not something that has happened.
Published by the source
The source this page is built from.
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Request accessAlready invited? Sign in
Carrywatch Pro is by invitation. An invite lets you buy Pro.
By email · Weekly